Elekta AB (publ) Asset Resilience Ratio
Elekta AB (publ) asset resilience ratio. Elekta AB (publ) (EKTA-B) has an Asset Resilience Ratio of 9.18% as of January 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read EKTA-B total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Elekta AB (publ) (2012–2025)
Asset resilience ratio of Elekta AB (publ) from 2012 to 2025. This chart shows how Elekta AB (publ)'s Asset Resilience Ratio has changed over time. See EKTA-B FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Elekta AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see EKTA-B asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr2.54 Billion | 9.18% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr2.54 Billion | 9.18% |
Asset Resilience Insights
- Limited Liquidity: Elekta AB (publ) maintains only 9.18% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Elekta AB (publ) Industry Peers by Asset Resilience Ratio
Compare Elekta AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
GN Store Nord
CO:GN |
Medical Devices | -4.56% |
|
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
SHG:688212 |
Medical Devices | 6.09% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
VIROMED MEDICAL NA O.N.
XETRA:VME |
Medical Devices | 0.03% |
|
Affluent Medical SAS
PA:AFME |
Medical Devices | 0.03% |
|
DRGEM Corporation
KQ:263690 |
Medical Devices | 2.12% |
Elekta AB (publ) Asset Resilience Ratio by Year (2012–2025)
Elekta AB (publ) asset resilience ratio by year from 2012 to 2025. The table below shows the annual Asset Resilience Ratio data for Elekta AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-04-30 | 10.20% | Skr2.96 Billion ≈ $318.01 Million |
Skr28.98 Billion ≈ $3.12 Billion |
+3.24pp |
| 2024-04-30 | 6.96% | Skr2.19 Billion ≈ $235.14 Million |
Skr31.41 Billion ≈ $3.38 Billion |
-0.64pp |
| 2023-04-30 | 7.60% | Skr2.25 Billion ≈ $242.14 Million |
Skr29.61 Billion ≈ $3.19 Billion |
-4.10pp |
| 2022-04-30 | 11.70% | Skr3.08 Billion ≈ $331.13 Million |
Skr26.30 Billion ≈ $2.83 Billion |
-1.07pp |
| 2021-04-30 | 12.77% | Skr3.17 Billion ≈ $341.36 Million |
Skr24.84 Billion ≈ $2.67 Billion |
-5.63pp |
| 2020-04-30 | 18.40% | Skr5.23 Billion ≈ $562.62 Million |
Skr28.41 Billion ≈ $3.06 Billion |
+8.42pp |
| 2019-04-30 | 9.98% | Skr2.40 Billion ≈ $258.49 Million |
Skr24.06 Billion ≈ $2.59 Billion |
+1.81pp |
| 2018-04-30 | 8.17% | Skr1.83 Billion ≈ $197.37 Million |
Skr22.46 Billion ≈ $2.42 Billion |
+2.09pp |
| 2017-04-30 | 6.08% | Skr1.27 Billion ≈ $137.00 Million |
Skr20.95 Billion ≈ $2.25 Billion |
+7.87pp |
| 2016-04-30 | -1.80% | Skr-349.00 Million ≈ $-37.56 Million |
Skr19.44 Billion ≈ $2.09 Billion |
-0.12pp |
| 2015-04-30 | -1.67% | Skr-354.00 Million ≈ $-38.10 Million |
Skr21.18 Billion ≈ $2.28 Billion |
-45.02pp |
| 2012-04-30 | 43.35% | Skr6.60 Billion ≈ $710.70 Million |
Skr15.23 Billion ≈ $1.64 Billion |
-- |
About Elekta AB (publ)
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers linear accelerator and radiation therapy products comprising Elekta Unity for anatomy-specific MR imaging; Elekta Evo that delivers offline and online adaptive radiation therapy; Elekta Versa … Read more